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Abstract The heart contains a collagen network that con-
tributes to the contractility of the heart and provides cardiac
strength. In cardiac diseases, an increase in collagen depo-
sition is often observed. This fibrosis formation causes
systolic and diastolic dysfunction, and plays a major role in
the arrythmogenic substrate. Therefore, accurate detection of
cardiac fibrosis and its progression is of clinical importance
with regard to diagnostics and therapy for patients with
cardiac disease. To evaluate cardiac collagen deposition, both
invasive and non-invasive techniques are used. In this review
the different techniques that are currently used in clinical and
experimental setting are summarised, and the advantages and
disadvantages of these techniques are discussed.
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Introduction
Cardiac tissue consists mainly of cardiomyoctyes, which are
surrounded by extracellular matrix. The major component of
theextracellularmatrixiscollagen.Differenttypesofcollagen
exist, and the fibrillar collagen types I and III are most abun-
dantinthemyocardium.Thesecollagenfibresformacollagen
network that provides cardiac strength during contractile
forces, and collagen fibres play a role in myocyte – myocyte
connections [1].
In virtually all cardiac diseases, an increase in collagen
deposition is observed, hence fibrosis. Two types of fibrosis
are distinguished: replacement and reactive fibrosis. When
cardiac cell death occurs, these cells are replaced by colla-
gen, called reparative fibrosis. However, fibrosis may also
develop without cell loss, e.g. due to increased mechanical
load. This type of collagen deposition is called reactive
fibrosis and is observed as patchy fibrosis in the myocardi-
um or large collagen strands in between the cardiomyocytes
(interstitial fibrosis). Both types of fibrosis lead to diastolic
and systolic dysfunction [2], and reactive fibrosis leads to an
increased susceptibility for cardiac arrhythmias [3].
For an appropriate prognosis and therapy of cardiac
patients, knowledge about collagen content and the progres-
sion of fibrosis formation is important. Various invasive and
non-invasive techniques are currently available to detect
collagen and new methods are still being developed. This
review focuses on detection techniques that are currently
used for cardiac collagen monitoring, both in the clinical
and experimental setting. Advantages and disadvantages of
the various techniques are discussed.
Collagen turnover
Collagen is not static, but is continuously synthesised and
degraded. Procollagen, the precursor of collagen, is synthes-
ised by fibroblasts as a triple helix molecule. Once procolla-
gen is transported from the fibroblast into the intercellular
space,propeptidesattheamino(N)- and carboxy (C)-terminus
of the procollagen are cleaved. The mature collagen will form
larger collagen fibrils that become part of the collagen network
[4]( F i g .1). Degradation of collagen is provided by matrix
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Collagen is synthesised at a rate of 5% per day. A similar
amount is degraded in the non-growing heart [5]. In dis-
eased myocardium, the equilibrium between collagen syn-
thesis and breakdown is disturbed, resulting in collagen
deposition.
Invasive techniques to detect collagen
Cardiac tissue biopsies harvested during surgery or with
catheters can be used to investigate the structural changes
in the myocardium. Although taking biopsies is unfavoura-
ble for the patient and not without risk, the collection of
tissue is still widely used and provides detailed information
about structural and electrical remodelling of the heart. The
disadvantage of a biopsy is that analyses of this biopsy only
provide information on a very localised area of the heart.
Histology
For a histological examination of the collagen content, sev-
eral routinely used and cheap dye stains can be used. For
this purpose tissue is frozen or embedded in paraffin and cut
in sections with a thickness of about 4–10 μm. Masson’s
Trichrome and Picriosirius Red are the most frequently used
stains for collagen. Masson’s Trichrome is based on three
dyes, of which Light Green or Aniline Blue are commonly
used to colour the collagen [6]. In the Picrosirius Red stain,
the Picrosirius Red, which is extremely acid, binds to colla-
gen [7]. Also phosphomolybdic acid, one of the dyes used in
Masson’s Trichrome, is able to bind collagen. Subsequently,
Light Green or Aniline Blue interacts [6]. Thus, binding of
these dyes is based on base–acid interactions, and may
therefore not be specific for collagen.
Since mature collagen is birefringent, and Picrosirius Red
can enhance the birefringency of collagen, stained collagen
fibres can be visualised better and in more detail using
polarised light. Whittaker et al. showed that analysis of
cardiac collagen with polarised light provides more insight
into the structure and composition of the collagen network,
as compared to Picrosirius Red or Masson’s Trichrome
staining [8].
To be more collagen specific, fluorescent labelled anti-
bodies can be used. Commercially available antibodies can
be used for specific protein investigations with Western blot
or immunohistology. This method is less frequently used,
mainly because antibodies are more expensive than dye
stains and immunohistology is more time-consuming. More-
over, when using immunofluorescent microscopy, auto-
fluorescence of the tissue may interfere with a quantitative
analysis.
CNA35
CNA35 is a truncated bacterial protein that binds to colla-
gen. Krahn et al. have shown that fluorescent labels can
easily be attached to CNA35 and that such fluorescent
probes are still highly specific for collagen. The authors
state that fluorescent labelled CNA35 provides the follow-
ing advantages when compared with antibodies: 1) the
probes have a high affinity to bind to collagen, but binding
is reversible (Kd010
−7–10
−6 M), which is a prerequisite for
imaging of collagen in viable tissue; and 2) labelled CNA35
is much smaller than antibodies, which might be beneficial
for an optimal penetration of tissue [9]. Moreover, the fluo-
rescent label at CNA35 can be replaced by a MRI tagged
label such as gadopentetate dimeglumine (Gd-DTPA; a
gadolinium-based contrast agent), which would allow spe-
cific collagen detection by MRI. Although in vivo studies
with mice showed no fluorescent staining in the myocardi-
um after intravenous injection of CNA35 [10], preliminary
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Fig. 1 Schematic overview
from the synthesis of procolla-
gen to embedding of the
collagen into the network 1.
Three procollagen strands,
synthesised by the fibroblast,
form procollagen with its triple
helical structure. 2. Procollagen
is transported into the extracel-
lular matrix and the propeptides
are cleaved. 3. The mature
collagen forms larger fibrils and
cross-links and is embedded in
the collagen network of the heart
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collagen detection with CNA35. In collagen-rich heart sec-
tions and in collagen-rich hearts where labelled CNA35 is
perfused via a Langendorff setup, the fluorescent signal is
detected in the sections and coincides with a Picrosirius Red
staining on serial sections (Fig. 2; personal communication
from R. Hermans, MSc., Prof. Dr. M. van Zandvoort, and
Prof. Dr. F. Prinzen, Maastricht University). Further re-
search is required to investigate whether labelled CNA35
can be used in monitoring cardiac collagen in vivo.
Hydroxyproline assay
The hydroxylation (introduction of a hydroxyl-group into an
organic compound) of proline within the collagen molecule
results in hydroxyproline. This modified amino acid stabil-
ises the triple helical structure in mature collagen [11]. Since
hydroxyproline is highly specific for collagen, hydroxypro-
line measurements accurately reflect the amount of collagen
in the tissue. Commercial kits are available to determine
hydroxyproline. Collagen contains 14% hydroxyproline,
hence the actual amount of collagen can easily be calculated.
However, for this analysis homogenised tissue samples are
required and will therefore provide no information on poten-
tial heterogeneity of deposition, which might be demanded in
e.g. ablation surgery. Despite this disadvantage, the hydroxy-
proline assay is still one of the most reliable techniques to
assess total collagen tissue levels.
Sircol assay
The commercially available Sircol assay is based on the
binding of Picrosirius Red to collagen in homogenised sam-
ples. In this assay tissue is homogenised with pepsin, and
only newly formed collagen is measured. This is because
only procollagen can be dissolved in pepsin, whereas cross-
linked collagen will remain insoluble [12]. The analysis is
easy to perform, but as with the hydroxyproline assay, the
assay does not provide any information about the site-
specific localisation of the collagen either.
Non-invasive techniques to detect collagen
Circulating biomarkers in the blood
When the C- and N-terminus of procollagen are cleaved
from procollagen, they are released into the bloodstream.
The N-terminus of procollagen III (PIIINP) and the C- and
N-terminus of procollagen I (PICP and PINP respectively)
can be detected in blood samples [13]. Circulating bio-
markers that reflect breakdown of the collagen are MMPs,
TIMPs, and one of the breakdown products of collagen I,
ICTP [13]. Several studies have investigated the levels of
these markers for various cardiac diseases, but results are
frequently conflicting [14].
The biomarkers mentioned before can be determined in
blood samples with commercially available assays. Advan-
tages of measuring biomarkers with these kits are that the
analysis is non-invasive, cheap, and easily applicable in the
clinical setting. However, the quantitative analysis of cardi-
ac fibrosis by these biomarkers is not yet validated [14].
Another limitation of these circulatory biomarkers is that
the circulating peptides are not cardiac-specific. As collagen I
is the most prominent collagen type in all tissues, the biomark-
erlevelsofcollagenIwill reflect thecollagentypeIturnoverin
the entire body. There are indications that the described bio-
markersalsoreflectcardiaccollagen:1)somebiomarkershave
a gradient from coronary sinus blood to peripheral blood, and
Fig. 2 Collagen detection with CNA35. The left panel shows a
coronal section of a mouse heart containing interstitial fibrosis that
is detected by CNA35 labelled with the fluorescent probe FITC.
Green 0 collagen, blue 0 nuclei. The right panel shows a serial
section of the mouse heart stained with Picrosirius Red, yellow 0
viable myocardium, red 0 collagen. CNA35-stained picture kindly
provided by Prof. Dr. Prinzen and Prof. Dr. van Zandvoort, Maas-
tricht University
46 Neth Heart J (2012) 20:44–482) levels in patients with cardiac disease differ from healthy
controls (reviewed in De Jong et al. [14]). However, it would
be of great advantage to look for circulating biomarkers that
specifically predict cardiac collagen. In this respect, micro-
RNAs (miRNAs) might be of particular interest. MiRNAs
are post-transcriptional regulators (short RNA strands) of a
number of genes. It has been shown that miRNAs such as
miR-29, miR-30, and miR-21 play a specific role in collagen
formation in the myocardium, as nicely reviewed by
Bauersachs [15]. Recent studies showed that miRNA levels
detected in blood samples were significantly changed in
patients with acute myocardial infarction [16] or with heart
failure [17] compared with healthycontrols. WhethermiRNAs
specifically involved in cardiac fibrosis formation are also
detectable in blood is currently unknown, but might be of
particular interest for specific collagen biomarkers.
MRI
Late gadolinium enhanced (LGE) MRI is frequently used in
clinics nowadays to assess cardiac scar tissue. Myocardial
scarring can be detected using MRI after administration of a
gadolinium-based contrast agent. Due to differences in
washout kinetics of scarred and viable tissue, the contrast
agent remains longer in scarred than in viable tissue [18].
Although this technique has greatly improved detection of
myocardial fibrosis in the clinical setting, the method has
some drawbacks. In the first place, it represents an indirect
method for collagen detection of collagen deposition. More-
over, currently only large areas of scarring can be detected
while small patches of fibrosis and increased interstitial
fibrosis are of particular interest in arrhythmia susceptibility
and systolic dysfunction.
Extensive research is still being performed to improve
fibrosis detection by imaging techniques. A recent study of
Messroghli et al. showed that patchy and interstitial cardiac
fibrosis in a hypertrophic rat model can be determined with
MRI T1 mapping based on a gadolinium-based contrast
agent. The authors showed a moderate though significant
correlation between myocardial extracellular volume mea-
sured by Gd-DTPA based T1 mapping and histological
analysis of cardiac fibrosis [19].
We have recently shown that ultrashort echo time (UTE)
MRI is another technique that can be used for detection of
myocardial fibrosis. UTE MRI can detect tissues with very
fast signal decay, such as tendons and bone. These compact
tissues are collagen-rich, and are thought to be detected by
UTE MRI since collagen has very fast signal decay. To
investigate whether cardiac collagen could be detected with
UTE MRI as well, we used a rat myocardial infarction
model. This study showed that UTE MRI is able to detect
myocardial fibrosis after infarction without the use of any
contrast agents [20].
Imaging techniques are favourable for the detection of
collagen since these techniques are non-invasive. However,
a major drawback of the use of imaging techniques for
detection of fibrosis is that quantification of the hyper-
enhanced signals on MR images is not yet standardised.
Flett et al. compared several quantification techniques for
LGE MRI images and showed that substantial differences
exist in the amount of fibrosis measured by the different
techniques. The full width half max (FWHM) technique
appeared the most reliable and reproducible quantification
technique [18].
Concluding remarks
Cardiac collagen plays an important role in cardiac disease,
because it may affect contractility and arrhythmogenicity.
Thus, detection of collagen in patients with heart disease is
of utmost importance. In this review several techniques that
are used or developed for collagen detection in the heart are
discussed. Both invasive and non-invasive techniques are
available. Histological and biochemical assessment of col-
lagen in cardiac tissue is still the most accurate method and
easy to quantify, especially the hydroxyproline assay, but
size-limited cardiac biopsies are required for these analyses.
Whereas the non-invasive techniques such as MRI and
circulating biomarkers are of great interest, quantitative
analysis of these techniques are not yet standardised and
validated respectively in patients.
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